Despite the pathophysiological and clinical differences between AD and PD, the basis for the use of GLP-1RAs in the treatment of these diseases is precisely the general mechanisms of their pathogenesis and risk factors, including T2DM and insulin resistance, abnormal accumulation of toxic proteins, increased inflammation, decreased synaptic function, loss of neurons, increased activation of astrocytes, leading to cognitive dysfunction [43]
Curcumin: The active compound in turmeric, which may support metabolic health and inflammation reduction
How much weight will I regain if I stop semaglutide
The article states that the IRS does not automatically approve weight-loss medications, and that eligibility rests on the medication being prescribed to treat a diagnosed condition, including obesity when medically indicated
Breastfeeding mothers interested in newer GLP-1 agonists should wait for specific safety data before considering them